Product
CYNK-101
1 clinical trial
1 indication
Clinical trial
A Phase I/IIa Open Label, Non-Randomized, Multicenter Study of CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) AenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-02-15